日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

治疗性配体通过削弱雌激素受体的移动性来拮抗雌激素受体的功能

Jane Guan, Wei Zhou, Marc Hafner, Robert A Blake, Cecile Chalouni, Irene P Chen, Tom De Bruyn, Jennifer M Giltnane, Steven J Hartman, Amy Heidersbach, Rene Houtman, Ellen Ingalla, Lorn Kategaya, Tracy Kleinheinz, Jun Li, Scott E Martin, Zora Modrusan, Michelle Nannini, Jason Oeh, Savita Ubhayakar, X

Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

更正:选择性雌激素受体下调剂 GDC-0810 在多种 ER+ 乳腺癌模型中均有效。

Joseph, James D; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P; Lai, Andiliy G; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L; Julien, Jackaline D; Nagasawa, Johnny Y; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M; Wertz, Ingrid E; Lackner, Mark R; Nannini, Michelle A; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L; Heyman, Richard A; Rix, Peter J; Friedman, Lori; Smith, Nicholas D; Metcalfe, Ciara; Hager, Jeffrey H

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

选择性雌激素受体下调剂 GDC-0810 对多种 ER+ 乳腺癌模型均有效

James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla, Kimberly Walter, Robert A Blake, Jim Nonomiya, Zhengyu Guan, Lorna Kategaya, Steven P Govek, Andiliy G Lai, Mehmet Kahraman, Dan Brigham, John Sensintaffar, Nhin Lu, Gang Shao, Jing Qian, Kate Grillot, Michael M

MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer

MMP-1 和 Pro-MMP-10 作为膀胱癌患者 FGFR3 靶向治疗的潜在尿液药效学生物标志物

Xiangnan Du, Benjamin C Lin, Qian-Rena Wang, Hao Li, Ellen Ingalla, Janet Tien, Isabelle Rooney, Avi Ashkenazi, Elicia Penuel, Jing Qing

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells

与匹配的原发肿瘤相比,膜黏蛋白MUC4在乳腺肿瘤淋巴结转移灶中表达升高,并赋予乳腺癌细胞侵袭性。

Workman, Heather C; Miller, Jamie K; Ingalla, Ellen Q; Kaur, Rouminder P; Yamamoto, Diane I; Beckett, Laurel A; Young, Lawrence Jt; Cardiff, Robert D; Borowsky, Alexander D; Carraway, Kermit L; Sweeney, Colleen; Carraway, Kermit L 3rd

Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer

抑制负调控因子LRIG1会导致乳腺癌中ErbB2过度表达

Miller, Jamie K; Shattuck, David L; Ingalla, Ellen Q; Yen, Lily; Borowsky, Alexander D; Young, Lawrence J T; Cardiff, Robert D; Carraway, Kermit L 3rd; Sweeney, Colleen